GGrantIndex
Sort

48,018 grants matching immunotherapy

Molecular mechanisms for antiviral signaling and regulation by MDA5 and TRIM65

$442,500
Sun Hur · Boston Children'S Hospital · R01 · FY2023 · AI

Outreach Core

$442,500
Wesley Tansey · Sloan-Kettering Inst Can Research · U54 · FY2025 · CA

Project III: Engineering immunogenic cell death in melanoma and renal cell carcinoma.

$442,500
Emily H Cheng · Sloan-Kettering Inst Can Research · U54 · FY2025 · CA

Molecular Mechanisms for Antiviral Signal Activation by MDA5 and RIG-I

$442,500
Sun Hur · Boston Children'S Hospital · R01 · FY2017 · AI

Control of Airway Tolerance

$442,500
Michael Croft · La Jolla Institute For Immunology · R01 · FY2015 · AI

Molecular mechanisms for antiviral signaling and regulation by MDA5 and TRIM65

$442,500
Sun Hur · Boston Children'S Hospital · R01 · FY2024 · AI

Structural and functional analyses of the RIG-I filament in innate immunity

$442,500
Sun Hur · Boston Children'S Hospital · R01 · FY2016 · AI

Molecular mechanisms for antiviral signaling and regulation by MDA5 and TRIM65

$442,500
Sun Hur · Boston Children'S Hospital · R01 · FY2020 · AI

Molecular Mechanisms for Antiviral Signal Activation by MDA5 and RIG-I

$442,500
Sun Hur · Boston Children'S Hospital · R01 · FY2016 · AI

Project II: Immune regulatory circuits in primary colon cancer and lymph node and liver metastases

$442,500
Alexander Y. Rudensky · Sloan-Kettering Inst Can Research · U54 · FY2025 · CA

Ultrasound imaging and enhanced therapeutic response

$442,475
Katherine W Ferrara · University Of California At Davis · R01 · FY2014 · CA

Immune regulation to Coccidioides infection

$442,470
Katrina K Hoyer · University Of California, Merced · R15 · FY2023 · AI

Combining AD Epitope Vaccine with Innate Immunity

$442,458
David Hastings Cribbs · University Of California-Irvine · R01 · FY2010 · NS

Macrophage mitochodrial reprogramming and innate immune memory

$442,368
Edward R Sherwood · Vanderbilt University Medical Center · R01 · FY2020 · AI

Therapeutic targeting of the tumor microenvironment in triple negative breast cancer patients at high risk of relapse and preclinical models of lung metastases

$442,343
Linda Theresa Vahdat · Dartmouth-Hitchcock Clinic · R01 · FY2025 · CA

Structural and functional analyses of the RIG-I filament in innate immunity

$442,292
Sun Hur · Boston Children'S Hospital · R01 · FY2015 · AI

Immune-mediated therapies in a genetically engineered murine model of diffuse intrinsic pontine glioma

$442,283
Maria G Castro · University Of Michigan At Ann Arbor · R21 · FY2019 · NS

Gene Edited and Engineered Tumor Cell Therapeutics for Cancer

$442,270
Khalid A Shah · Brigham And Women'S Hospital · R01 · FY2023 · NS

Targeting melanoma promoting RNA modification pathway for melanoma therapy.

$442,236
Narendra Wajapeyee · University Of Alabama At Birmingham · R01 · FY2025 · CA

Cellular Processing Core

$442,231
Ian McNiece · Johns Hopkins University · P01 · FY2007 · CA

Leukemia Specific Splice Isoforms as Neo-Antigens for T-Cell Immunotherapy

$442,225
Paul Michael Armistead · Univ Of North Carolina Chapel Hill · R01 · FY2016 · CA

Platelet Serine/Threonine Phosphatases in Cancer Pathophysiology

$442,222
K. Vinod Vijayan · Baylor College Of Medicine · R01 · FY2021 · CA

(PQ10) The impact of the gut microbiome on the anti-tumor effects of radiotherapy

$442,221
Andrea Facciabene · University Of Pennsylvania · R01 · FY2021 · CA

Mechanisms by which effector T cells modulate endogenous remyelination

$442,217
Peter A Calabresi · Johns Hopkins University · R01 · FY2025 · NS

Targeting MUC1-C with an antibody drug conjugate for the therapy of advanced prostate cancer

$442,214
Donald W. Kufe · Dana-Farber Cancer Inst · R21 · FY2022 · CA